

Supplementary Table 1. Clinical characteristics of the (A) original cohort and (B)

three independent cohort of patients according to high or low risk of the 4-gene signature.

Supplementary Table 1A.

Characteristic	Patients with high risk gene signature*	Patients with low risk gene signature*	P value
	No. (%)	No. (%)	
<b>Original cohort (n=111)</b>	n=55	n=56	
<b>Age (mean±SD)</b>	65.5±9.05	64±9.99	.41 <sup>†</sup>
<b>Gender</b>			
Male	32 (58)	31 (55)	.8487 <sup>‡</sup>
Female	23 (42)	25 (45)	
<b>Stage</b>			
I and II	39(70)	46 (82)	.1845 <sup>‡</sup>
III and IV	16 (30)	10 (18)	
<b>Cell type</b>			
Adenocarcinoma	32 (58)	26(46)	.2561 <sup>‡</sup>
Squamous cell carcinoma	23 (42)	30 (54)	

\* Classified according to 4-gene signature

<sup>†</sup>T test.

<sup>‡</sup>Fisher's exact test.

Supplementary Table 1B. (cont).

Characteristic	Patients with high	Patients with low risk	P value
	risk gene signature* No. (%)	gene signature* No. (%)	
<b>VGHTC (n=69)</b>	n=34	n=35	
<b>Age (mean±SD)</b>	69.4±10.67	64.7±10.40	.6383 <sup>†</sup>
<b>Gender</b>			
Male	32 (94)	26 (74)	.0451 <sup>‡</sup>
Female	2 (6)	9 (26)	
<b>Stage</b>			
I and II	19 (56)	23 (66)	.4646 <sup>‡</sup>
III	15 (44)	12(34)	
<b>Cell type</b>			
Adenocarcinoma	9 (26)	18 (51)	.0923 <sup>§</sup>
Squamous cell carcinoma	22 (65)	14(40)	
Other	3 (9)	3 (9)	
<b>CAN/DF and MSK (n=186)</b>	n=93	n=93	
<b>Age (mean±SD)</b>	63.9±9.17	64.7±10.40	.3408 <sup>†</sup>
<b>Gender</b>			
Male	45 (48)	38 (41)	.3762 <sup>‡</sup>
Female	48 (52)	55 (59)	
<b>Stage</b>			
I and II	84 (90)	81 (87)	.644 <sup>‡</sup>
III	9 (10)	12 (13)	
<b>UM and HLM (n=257)</b>	n=128	n=129	
<b>Age (mean±SD)</b>	65.3±10.59	65.3±9.84	.9744 <sup>†</sup>
<b>Gender</b>			
Male	75 (59)	66 (51)	.26 <sup>‡</sup>
Female	53 (41)	63 (49)	
<b>Stage</b>			
I and II	104 (81)	106 (82)	.873 <sup>‡</sup>
III	24 (19)	23(18)	

\*Classified according to 4-gene signature

<sup>†</sup>T test. <sup>‡</sup>Fisher's exact test. <sup>§</sup>Chi-square test.

